Prefer Newsweek on Google to see more of our trusted coverage when you search. A brand new drug might be more effective at preventing HIV than current methods. Many people take daily oral ...
A new type of PrEP injection, requiring only three injections a year, could be on the way. The FDA approved injections of cabotegravir in 2021 as a form of PrEP, to minimize the risk of acquiring HIV.
Daily oral PrEP (generic Truvada; Descovy) is effective but adherence-sensitive, and seroconversions in trials correlate with ...
The US Food and Drug Administration has approved a form of PrEP that requires injections every two months, rather than a daily pill. PrEP, or pre-exposure prophylaxis, uses antiretroviral medications ...
Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The company revealed its results at this week’s Conference on Retroviruses and ...
The U.S. Food and Drug Administration has approved a highly effective HIV prevention drug that outperforms oral medications in stopping HIV transmission. Developed by Gilead Sciences, the drug ...
Lenacapavir, a twice-yearly injectable antiretroviral, demonstrated 100% effectiveness for preventing HIV acquisition in a large study of young cisgender women in Africa, Gilead Sciences announced ...
Laura holds a Master's in Experimental Neuroscience and a Bachelor's in Biology from Imperial College London. Her areas of expertise include health, medicine, psychology, and neuroscience. Laura holds ...
Twice-yearly lenacapavir (Sunlenca) substantially reduced HIV infection when used for preexposure prophylaxis (PrEP) in cisgender men and transgender or gender-nonbinary persons in the pivotal PURPOSE ...
Dr Jane Ruth Aceng says Uganda is committed to ending AIDS as a public health threat by 2030 through a combination prevention ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results